<< Back To Search

Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma

Notify the Multiple Myeloma Research Foundation You Are Interested In This Trial


Third Opinion Trial Synopsis:
This is a study for people with a type of cancer called multiple myeloma who have already tried two other treatments that didn't work. There are three parts to the study: a screening phase, a phase where the person gets a new treatment for 28 days, and a follow-up phase. The new treatment includes three medications called isatuximab, elotuzumab, pomalidomide, and dexamethasone.
*Third Opinion AI Generated Synopsis

Trial Summary
This is a multicenter, open-label phase II study in subjects with relapsed and/or refractory multiple myeloma with at least two prior lines of therapy. The main study consists of three phases: a 28-day screening phase, treatment phase that consists of 28-day cycles of isatuximab with elotuzumab, pomalidomide, and dexamethasone and a follow-up phase.

Locations & Contact

Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.

Is There Anything Else You Would Like To Share?